Last reviewed · How we verify
Prevention of Seizures following Cranial Trauma or Surgery — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Phenytoin Sodium | PHENYTOIN | Viatris | Anti-epileptic Agent | Sodium channel protein type 2 subunit alpha | 1953-01-01 | |
| Dilantin | Phenytoin Sodium | Pfizer | phenytoin | Nuclear receptor subfamily 1 group I member 3 | 1953-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Prevention of Seizures following Cranial Trauma or Surgery
- Viatris · 1 drug in Prevention of Seizures following Cranial Trauma or Surgery
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Prevention of Seizures following Cranial Trauma or Surgery:
- Prevention of Seizures following Cranial Trauma or Surgery treatment updates — RSS
- Prevention of Seizures following Cranial Trauma or Surgery treatment updates — Atom
- Prevention of Seizures following Cranial Trauma or Surgery treatment updates — JSON
Cite this brief
Drug Landscape (2026). Prevention of Seizures following Cranial Trauma or Surgery — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-seizures-following-cranial-trauma-or-surgery. Accessed 2026-06-10.
Related
- Prevention of Seizures following Cranial Trauma or Surgery full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing